157 related articles for article (PubMed ID: 27987587)
1. Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.
Gibelin C; Avrillon V; De La Fouchardiere A; Mc Leer-Florin A; Lantuejoul S; Fayette J
Lung Cancer; 2016 Dec; 102():42-43. PubMed ID: 27987587
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
3. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M
Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
[TBL] [Abstract][Full Text] [Related]
5. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
[TBL] [Abstract][Full Text] [Related]
6. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A
Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857
[TBL] [Abstract][Full Text] [Related]
7. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
[TBL] [Abstract][Full Text] [Related]
8. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
Bos M; Gardizi M; Schildhaus HU; Heukamp LC; Geist T; Kaminsky B; Zander T; Nogova L; Scheffler M; Dietlein M; Kobe C; Holstein A; Maintz D; Büttner R; Wolf J
Lung Cancer; 2013 Jul; 81(1):142-3. PubMed ID: 23558310
[TBL] [Abstract][Full Text] [Related]
9. [Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib].
Svaton M; Pešek M
Klin Onkol; 2016; 29(1):63-5. PubMed ID: 26879065
[TBL] [Abstract][Full Text] [Related]
10. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
Lu S; Azada MC; Ou SH
Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
[TBL] [Abstract][Full Text] [Related]
11. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
[TBL] [Abstract][Full Text] [Related]
12. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
13. A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer.
Viola P; Maurya M; Croud J; Gazdova J; Suleman N; Lim E; Newsom-Davis T; Plowman N; Rice A; Montero MA; Gonzalez de Castro D; Popat S; Nicholson AG
J Thorac Oncol; 2016 Jul; 11(7):1029-39. PubMed ID: 27179848
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adoloscents and young adults.
Scarpino S; Rampioni Vinciguerra GL; Di Napoli A; Fochetti F; Uccini S; Iacono D; Marchetti P; Ruco L
Lung Cancer; 2016 Jul; 97():95-8. PubMed ID: 27237034
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.
Juan O; Popat S
Lung Cancer; 2017 Feb; 104():131-133. PubMed ID: 27863911
[No Abstract] [Full Text] [Related]
16. ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma.
Houang M; Toon CW; Clarkson A; Sioson L; de Silva K; Watson N; Singh NR; Chou A; Gill AJ
Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):134-8. PubMed ID: 24992173
[TBL] [Abstract][Full Text] [Related]
17. A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib.
Ju L; Han M; Su J; Wu C; Dong Z
Cancer Chemother Pharmacol; 2018 Sep; 82(3):561-564. PubMed ID: 30083883
[TBL] [Abstract][Full Text] [Related]
18. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.
Mikes RE; Jordan F; Hutarew G; Studnicka M
Lung Cancer; 2015 Dec; 90(3):614-6. PubMed ID: 26519123
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib in ROS1 rearranged non-small cell lung cancer (NSCLC), from response to resistance.
Zhong E; Huang H
BMJ Case Rep; 2016 Oct; 2016():. PubMed ID: 27797842
[TBL] [Abstract][Full Text] [Related]
20. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
